Kornimate/medical-research-clean huggingface dataset:
cricket study, coronary calcium scores in patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: patients with chronic kidney disease (ckd) have been shown to have high coronary calcium scores (cac), but the temporal association between glomerular filtration rate, cvd risk factors and cac has not been described. this is a single-center, longitudinal, observational study. subjects included adults aged 18 years to 65 years old without preexisting coronary artery disease (cad). the ckd subjects (gfr \ /=60ml/min) were recruited. laboratory measurements and mdct scan were performed at baseline and after 12 months. baseline cac and average intact parathyroid hormone (ipth) level were significantly greater in the ckd group. baseline cac scores of the ckd group were twice the value of the control group; however, cac scores over one year were unchanged from baseline.

patients with chronic kidney disease (ckd) have been shown to have high coronary calcium scores (cac), but the temporal association between glomerular filtration rate, cvd risk factors and cac has not been described. this is a single-center, longitudinal, observational study. subjects included adults aged 18 years to 65 years old without preexisting coronary artery disease (cad). the ckd subjects (gfr \ /=60ml/min) were recruited from the internal medicine clinic. laboratory measurements and mdct scan were performed at baseline and after 12 months. baseline cac and average intact parathyroid hormone (ipth) level were significantly greater in the ckd group. baseline cac scores of the ckd group were twice the value of the control group; however, cac scores over one year were unchanged from baseline. these observations suggest that cac begins in earlier stages of ckd. moreover, novel cvd risk factors including ipth may accelerate cad progression in ckd.

Eligibility criteria:
inclusion criteria: * male and female ages 18 to 65 years * chronic kidney disease patients, gfr \<60ml/min as defined by mdrd (levey) formula. * healthy volunteer controls, gfr \>/= 60 ml/min * signed, written informed consent exclusion criteria: * ages \ 65 years * pregnant subjects * subjects with history of severe obstructive pulmonary disease, chf, stroke, arrythmia. * dialysis and kidney transplant patients.

Keywords: chronic kideny disease hypertension
clinical and patient-reported outcomes after total wrist arthroplasty and total wrist arthrodesis

Conditions: Wrist Arthritis

Summary: the wrist is often considered to be the fundament of the hand. patients with a destroyed wrist joint caused by osteoarthritis or rheumatoid arthritis may suffer from pain and functional disabilities with impaired life quality. the traditional surgical solution for advanced wrist arthritis is a total wrist fusion (twf). although twf creates a stable wrist with minimal pain, the prize is the joint motion. total wrist arthroplasty (twa) is a motion-preserving alternative, but has failed to achieve the widespread use of other joint replacement procedures. twa is more costly and technically demanding than twf, and also associated with more complications. in addition, there is no consensus regarding the functional benefit of a twa compared to twf since prospective, comparative studies are missing. aim: the purpose of this prospective cohort study was to compare functional outcome and activity limitations up to two years after surgery with twa or twf.

patients with advanced wrist arthritis engaging both the midcarpal- and radiocarpal joints may suffer from pain, decreased joint motion and reduced grip strength. the traditional surgical solution with twf creates a stable wrist with decreased pain, but the prize is the loss of wrist motion. twa may be a motion-preserving alternative, but is more technically demanding and is associated with more complications compared to twf. in addition, the functional benefits of twa over twf are still unknown. aim: the purpose of this prospective cohort study was to compare functional outcome and activity limitations up to two years after surgery with twa or twf. methods: in this single-center prospective, longitudinal cohort-study, all patients treated with twf or twa due to end-stage wrist arthritis at one hand surgical department between march 1, 2015, through february 28, 2020, were enrolled.the treatment method was decided by the treating consultant in hand surgery, based on clinical evaluation of the patient and radiographic appearance of the wrist, in combination with the patients' own requests and prerequisites. assessments were performed at baseline, 3 months, 6 months, 12 months and 24 months after surgery with patient-reported outcome measures, range-of-motion, grip strength and radiographic evaluation.

Eligibility criteria:
inclusion criteria: * age 18 or older * both radoiocarpal and mid carpal arthritis due to osteoarthritis, inflammatory arthritis (such as rheumatoid/psoriasis arthritis), kienböck's disease exclusion criteria: * wrist problems due to hypermobility or cerebral palsy * severe cognitive disorder and unable to fill in questionnaires
oncolytic adenovirus(h101) combined with pd-1 inhibitors in patients with advanced malignant pleural mesothelioma

Conditions: Malignant Pleural Mesothelioma, Advanced

Summary: the purpose of this study is to evaluate the efficacy and safety of oncolytic adenovirus(h101) combined with pd-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced pd-1 inhibitors.

by monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (pd-1) inhibitors, we analyze and explore the effectiveness and safety of using oncolytic virus drugs. exploring the influencing factors of using oncolytic adenovirus injection combined with pd-1 inhibitors to reverse immune resistance in mpm patients. evaluate the safety of the drug, and finally evaluate the quality of life of patients using oncolytic adenovirus injection(h101) combined with pd-1 inhibitors.

Eligibility criteria:
inclusion criteria: 1. age 18-75 years old (including boundary values), regardless of gender. 2. confirmed as late stage mpm patients who have failed immunotherapy. 3. the patient or their legal representative can understand and sign the informed consent form. 4. at least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral ct ≥ 1cm or ordinary ct ≥ 2cm, and can be measured through imaging methods. 5. ecog score 0-2. exclusion criteria: 1. physicians participating in the study believe that patients may not be able to provide continuous follow-up information. 2. any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases). 3. contraindications to relevant drugs (such as oncolytic adenoviruses, pd-1 inhibitors, etc.)

Keywords: malignant pleural mesothelioma, advanced oncolytic adenovirus programmed death receptor
chemokine receptor 4 pet/ct imaging of cxcr4-related diseases

Conditions: CXCR4-related Disease; Tumor; Positron Emission Tomography; Metastasis

Summary: to evaluate the potential usefulness of 68ga/18f-pentixafor/pentixather positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various cxcr4-related disease patients.

subjects with various cxcr4-related disease patients underwent 68ga/18f-pentixafor/pentixather pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga/18f-pentixafor/pentixather pet/ct were calculated.

Eligibility criteria:
inclusion criteria: * suspected or confirmed untreated lymphoproliferative and other cxcr4-related diseases patients * 18f-fdg pet/ct within two weeks * signed written consent. exclusion criteria: * pregnancy * breastfeeding * known allergy against pentixafor

Keywords: pet/ct chemokine receptor 4 pentixafor pentixather
management of dry eye disease after cataract surgery with topical hyaluronic acid and gingko biloba

Conditions: Dry Eye Syndromes

Summary: cataract surgery is one of the main causes of dry eye disease (ded). this paper aimed at evaluating the prevalence of iatrogenic ded on a population of patients without ded receiving cataract surgery, and the impact of an eyedrop containing hyaluronic acid and gingko biloba (ha-gb, trium free eyedrops, sooft srl, italy). in this phase-iv trial we enrolled 40 patients with no ded. patients were seen at baseline, day 1, week 1 and week 4. at each visit patients received ocular surface disease index (osdi) questionnaire, anterior segment ophthalmoscopy with grading of conjunctival hyperemia, fluorescein tear break-up time (tbut), grading of fluorescein corneal staining (epithelial damage); adherence and tolerability using a visual analogue scale were checked at week 1 and 4. at day 0 patients underwent cataract surgery (2.4 mm temporal incision) and were randomized to standard postoperative care (control group) or standard postoperative care + ha-gb given three times a day for 4 weeks (ha-gb group).


Eligibility criteria:
inclusion criteria were: * at least 18 years old cataract requiring surgery * tbut of 7" or more in both eyes. exclusion criteria were: * but of 6 seconds or less in one or both eyes * corneal staining of grade 2 or more using oxford scale in one or both eyes * presence of corneal neuropathy (cochet-bonnet esthesiometry less than 50 mm) in one or both eyes * contact lens wear less than 30 days before surgery * neuropathic causes of dry eye (diabetes, long-standing contact lens wearing, previous ocular herpes infections) * autoimmune diseases * past or active ocular surface diseases (any corneal disease, cicatricial conjunctivitis, ocular surface burns, keratinization of the eyelid margin, sjogren syndrome, corneal trauma) * pregnant and lactating women pediatric patients or adolescents under 18 years * ocular or general factors predisposing the patient to an increased risk for intraoperative complications, according to investigator's evaluation. these include (but are not limited to) pseudoexfoliation capsulae, complete cataract, iridodonesis, previous eye surgery, previous eye trauma, history of complicated cataract surgery in the fellow eye, benign prostatic hyperplasia under treatment.
heat therapy in treating patients with unresectable primary or metastatic liver cancer

Conditions: Liver Cancer; Metastatic Cancer

Summary: rationale: heating tumors to several degrees above body temperature may kill tumor cells. purpose: phase ii trial to study the effectiveness of heat therapy in treating patients who have unresectable primary or metastatic liver cancer.

objectives: i. determine the efficacy of radiofrequency ablation in patients with primary or metastatic liver cancer. ii. determine disease free survival, local recurrence rate in treated lesions as compared to known recurrence rates after hepatic cryoablation, and overall survival in this patient population receiving this regimen. outline: patients undergo laparoscopic or open laparotomy surgical procedure to identify unresectable tumors by ultrasound. tumors are heated to a target temperature by electrodes for a maximum of 20 minutes. to achieve a 1 cm margin of ablated tissue around each lesion, multiple ablation courses may be performed, depending on the size of the lesions and the time required to complete the treatment. patients may be retreated if tumor recurs or new disease appears. patients are followed at 1 month, every 3 months for the first 2 years, every 6 months for next 3 years, and then annually thereafter. projected accrual: a maximum of 59 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: diagnosis of unresectable malignant primary or metastatic liver tumors tumors are deemed unresectable based on the following factors: 1-10 liver tumors bilobar liver tumors location of 1 or more lesions near a major intrahepatic vascular structure (hepatic vein, portal vein, vena cava) severe cirrhosis to preclude a major liver resection no unresectable extrahepatic disease prior failure of other therapeutic modalities allowed no more than moderate ascites no hepatic encephalopathy patient characteristics: age: any age performance status: zubrod 0-1 life expectancy: at least 3 months hematopoietic: not specified hepatic: no severe liver dysfunction (child's class c) bilirubin no greater than 3.0 mg/dl albumin no greater than 3.0 mg/dl pt no greater than 50% above normal renal: no renal dysfunction creatinine less than 2.0 mg/dl other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no altered mental status no active infection prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 4 weeks since prior chemotherapy endocrine therapy: not specified radiotherapy: at least 4 weeks since prior radiotherapy surgery: see disease characteristics

Keywords: stage iii childhood liver cancer stage iv childhood liver cancer recurrent childhood liver cancer localized unresectable adult primary liver cancer advanced adult primary liver cancer recurrent adult primary liver cancer liver metastases
feasibility of a deep learning-based algorithm for non-invasive assessment of vulnerable coronary plaque

Conditions: Chronic Coronary Syndrome; Coronary Artery Disease; Stable Angina; Acute Coronary Syndrome

Summary: the primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the dl-based algorithm with respect to correct identification of the plaque and associated vulnerability grade.

data collected in this study will be used for technology development, scientific evaluation, education, and regulatory submissions for future products. this is a pre-market, open label, prospective, non-randomized clinical research study conducted at one site in italy. the product being researched is the deep learning-based (dl) algorithm for non-invasive detection of vulnerable coronary plaque.

Eligibility criteria:
inclusion criteria: 1. patients referred for a clinically indicated ccta and ica with oct imaging examinations; 2. diagnosis of chronic coronary syndrome, known cad, or stable angina; and, 3. patients with acs that may undergo a ccta and not refer directly to the cath lab for revascularization procedures. exclusion criteria: 1. contradictions to contrast; 2. contraindications for beta blocker; 3. bmi \>30; 4. high heart rate ≥75 bpm; 5. atrial fibrillation; 6. arrythmia or irregular heartbeats; 7. any prior coronary revascularization; 8. presence of pacemaker or implantable cardioverter defibrillator; or, 9. patients with tavi/tavr.

Keywords: coronary ct angiography invasive coronary angiography optical coherence tomography vulnerable coronary plaque
a randomized controlled trial of a pre-transplant education intervention

Conditions: Kidney Transplant; Patient Education; Quality of Life

Summary: a multi-center, randomized, controlled clinical trial will be conducted to test the effectiveness of a home-based video intervention on improving kidney transplant candidate's knowledge, self-efficacy, quality of life, beliefs in medications, and education satisfaction as compared to usual care.

kidney transplantation is the best treatment for most patients with end-stage kidney disease, but it is an extremely complicated process. to become active on the transplant waitlist, patients must learn new information, navigate the healthcare system and undergo several specialized tests. after the transplant, another set of challenges emerge. transplant recipients must commit to lifelong therapy with immunosuppressive medications and adapt to lifestyle changes. up to half of all patients have difficulty taking the medications as prescribed, which can lead to transplant rejection, kidney loss, and death. the transplant process is challenging and confusing; however, increasing education and support to transplant candidates demands greater use of care providers' time and resources in a health care system that is already stretched. a patient-oriented video series has been developed according to best practices for transplant education, featuring an animated character embarking on a transplant journey. animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives provide support and encouragement. a multi-center, randomized, controlled clinical trial will be conducted to test the effectiveness of a home-based video intervention on improving kidney transplant candidate's knowledge, self-efficacy, quality of life and beliefs in medications as compared to usual care. participants will be randomized (1:1) to the control group, or the intervention group, who will be provided access to the video series, in addition, to standard of care. differences in changes in transplant knowledge, self-efficacy, beliefs about medicines, quality of life, and education satisfaction will be evaluated by a pre-and post-intervention survey. a thorough assessment of video-viewing habits and satisfaction with the intervention will provide insight on the feasibility of expanding home-based education to other health settings.

Eligibility criteria:
inclusion criteria: * 18 or older * can speak and understand and read english * are being assessed or wait-listed for kidney transplantation exclusion criteria: * do not meet inclusion criteria

Keywords: video patient education
modified diabetes prevention program in ecuador

Conditions: PreDiabetes

Summary: this pilot study will evaluate the use of a modified (cultural and language) adaptation of the national diabetes prevention program in a cohort in quito ecuador.

this pilot study will evaluate the use of a modified (cultural and language) adaptation of the national diabetes prevention program in a cohort in quito ecuador. people who took the program had the option to participate in the research component. all participants selected the research component. adaptations- the coaches will be physicians from puce and they will administer this program for eligible employees who have biochemical prediabetes. the program will be modified to be able to fit within the school curriculum. the diabetes prevention program will be offered in spanish and the content modified to better fit the cultural norms for the quito ecuador population. participants will be adults with prediabetes as screened by the cdc diabetes risk test and confirmed by hba1c. outcome measures will include change in mean hba1c, change in weight, physical activity, and attendance to the program.

Eligibility criteria:
inclusion criteria: adults who worked at the university and had biochemical prediabetes. - exclusion criteria: those with known diabetes, those unwilling to complete a 6 month intervention. -
chewing gum facilitates an earlier return to bowel function in pediatric scoliosis patients: a prospective randomized study

Conditions: Scoliosis

Summary: the purpose of this study is to evaluate the effectiveness of chewing gum on reducing post-operative ileus and reducing post-operative gastrointestinal symptoms in pediatric patients undergoing surgical correction of scoliosis. this study would provide minimal risk to its study population, and has the opportunity to provide a benefit to patients undergoing scoliosis surgery. if shown to be effective, this could lead to changes and improvement of the post-operative course for pediatric scoliosis patients.


Eligibility criteria:
inclusion criteria: * otherwise meets criteria for surgical correction of scoliosis * mental capacity to understand the purpose of the study * idiopathic scoliosis or neuromuscular scoliosis with mild cerebral involvement * posterior surgery approach only exclusion criteria: * unable to safely chew gum due to oropharyngeal issues or airway issues * history of gi surgery (g-tube, fundoplication, ostomy etc...) * anterior approach
comparison of corticosteroids vs placebo on duration of ventilatory support during severe acute exacerbations of copd patients in the icu

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the main objective of this study is to determine if the systemic (intravenous) administration of corticosteroids, as compared to placebo, increases the number of ventilator-free days (vfd) and alive at day 28 in copd patients admitted to an icu, a step-up unit or a respiratory care unit for an acrf requiring ventilatory support, either invasive or non-invasive.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥ 40 years 2. strongly suspected or documented copd, defined by the presence of the following criterias: * persistent respiratory symptoms (dyspnoea, chronic cough or sputum) * history of exposure to a risk factor such as tobacco smoke * if available, pulmonary function tests showing airflow limitation not fully reversible (post-bronchodilator ratio of fev1/ fvc ratio \< 0.7) 3. acrf, defined by the presence of the two following criteria: * copd exacerbation defined by a change in the patient baseline respiratory symptoms at least 24 hours and requiring a change in regular respiratory medication * acute respiratory failure \<24h (polypnea ≥ 30 breaths.min-1 or use of accessory respiratory muscles) requiring ventilatory support, either invasive (implemented because of respiratory distress) or niv (implemented because of hypercapnic acidosis with paco2 ≥ 45 mmhg and ph ≤ 7.35). 4. admission to an icu, a step-up unit or a respiratory care unit 5. inform consent from the patient or his surrogates. in patients who are not able to consent on admission an emergency inclusion procedure will be allowed, with a mandatory delayed consent. 6. affiliation to (or benefit from) french health insurance system exclusion criteria: * previous diagnostic of asthma, according to "gina" international guidelines (40) * recent use of systemic corticosteroids, defined by systemic corticosteroids use in the past 7 days * contra-indication of systemic corticosteroids treatment: allergy to corticosteroids, uncontrolled severe arterial hypertension, uncontrolled diabetes mellitus, gastro-intestinal ulcer bleeding * pneumothorax at randomization * extracorporeal life support (ecmo or ecco2r) at inclusion * moribund patient life expectancy \< 3 months * pregnancy * patients protected by law * exclusion period due to other interventional clinical trial enrolment which can influence primary outcome * previous inclusion in the present study
treatment of philadelphia-positive acute lymphocytic leukemia (ph+ all) in the elderly with imatinib mesylate (sti571) and chemotherapy.

Conditions: Acute Lymphocytic Leukemia

Summary: all patients aged 55 years or older were treated with steroids during one week and ph+ve cases were then offered a specific therapy including an induction treatment with steroids, cyclophosphamide, daunorubicin and vincristine, followed, irrespective of response to induction chemotherapy, by imatinib, 600 mg daily, combined with intermittent steroids during 2 months. patients in complete response (cr) were then given 10 blocks of alternating chemotherapy, including 2 additional two-month blocks of imatinib, for a total treatment duration of 2 years. therapy of occult central nervous system leukemia included 5 intrathecal injections of methotrexate and cranial irradiation. duration of therapy : 2 years.


Eligibility criteria:
inclusion criteria: * ph+ all patients * 55 years or older * signed written informed consent exclusion criteria: * cml in transformation * concomitant malignancy * previous treatment by imatinib * severe organ condition

Keywords: acute lymphocytic leukemia, ph+, elderly patients, imatinib